Paradigm Biocapital Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,330,508	Closed	-$95.3M	–	44
2024 Q2	$95.3M	Hold	2,330,508	–	–	3.65%	9
2024 Q1	$98.5M	Hold	2,330,508	–	–	3.47%	12
2023 Q4	$98.8M	Sell	2,330,508 -202,464	-8%	-$5.82M	4.63%	9
2023 Q3	$55.3M	Buy	2,532,972 +664,026	+36%	+$16.6M	3.75%	13
2023 Q2	$59.4M	Buy	1,868,946 +273,747	+17%	+$8.4M	4.59%	6
2023 Q1	$38.9M	Buy	+1,595,199	New	+$46.8M	3.69%	14

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Paradigm Biocapital Advisors's CERE Position: Q3 2024 in Review

Paradigm Biocapital Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,330,508 shares — an estimated $95.3M sold.

Paradigm Biocapital Advisors first reported a position in CERE in Q1 2023 and held it in 6 quarters. The position peaked at $98.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Paradigm Biocapital Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Paradigm Biocapital Advisors sold 2,330,508 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $95.3M.
Paradigm Biocapital Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Paradigm Biocapital Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $98.8M in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.